Gain Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · AccumulatedOtherComprehensive · · Accumulated · · · | |||||||||||||||||
| Three Months Ended March 31, 2026 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||
| Balance as of December 31, 2025 | | 42,073,807 | | $4,209 | | $119,139,677 | | $776,869 | | $(101,356,007) | | $18,564,748 | |||||
| Issuance of shares in ATM offering (Note 13) | | 184,662 | | | 18 | | | 427,765 | | | — | | | — | | 427,783 | |
| Stock-based compensation (Note 14) | | — | | | — | | | 401,032 | | | — | | | — | | 401,032 | |
| Exercise of warrants (Note 13) | | 229,710 | | | 23 | | | 2,040 | | | — | | | — | | 2,063 | |
| RSU vesting (Note 14) | | 399 | | | — | | | — | | | — | | | — | | | — |
| Changes in defined benefit pension plan obligation (Note 10) | | — | | | — | | | — | | | (767) | | | — | | | (767) |
| Foreign currency translation | | — | | | — | | | — | | | 220,850 | | | — | | | 220,850 |
| Net loss | | — | | | — | | | — | | | — | | | (5,608,732) | | | (5,608,732) |
| Balance as of March 31, 2026 | | 42,488,578 | | $4,250 | | $119,970,514 | | $996,952 | | $(106,964,739) | | $14,006,977 | |||||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · Accumulated Other Comprehensive · · Accumulated · · · | |||||||||||||||||
| Three Months Ended March 31, 2025 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||
| Balance as of December 31, 2024 | | 27,132,588 | | $2,713 | | $88,779,318 | | $(247,549) | | $(81,194,908) | | $7,339,574 | |||||
| Issuance of shares in at-the-market ("ATM") offering (Note 13) | | 1,094,701 | | | 109 | | | 2,419,210 | | | — | | | — | | 2,419,319 | |
| Stock-based compensation (Note 14) | | 63,859 | | | 6 | | | 423,139 | | | — | | | — | | 423,145 | |
| Exercise of warrants (Note 13) | | 454,893 | | | 47 | | | — | | | — | | | — | | | 47 |
| Changes in defined benefit pension plan obligation (Note 10) | | — | | | — | | | — | | | 4,826 | | | — | | | 4,826 |
| Foreign currency translation | | — | | | — | | | — | | | 122,858 | | | — | | 122,858 | |
| Net loss | | — | | | — | | | — | | | — | | | (4,530,058) | | | (4,530,058) |
| Balance as of March 31, 2025 | | 28,746,041 | | $2,875 | | $91,621,667 | | $(119,865) | | $(85,724,966) | | $5,779,711 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.